Verified Clinical Trials starts in Japan with MRJ & JACIC to prevent duplicate trial subjects

Overview

Verified Clinical Trials, a global leader in clinical trial subject registry solutions, has officially launched operations in Japan through a collaboration with Medical Revolutions Japan (MRJ) and the Japan Association of Contract Institutes for Clinical Pharmacology (JACIC) to address the growing global challenge of duplicate and professional research subjects in clinical trials.

Concerns for continuous trial subject duplication

• For the past thirty years, Japan’s only system for preventing duplicate subject registration was developed by JACIC and used across phase 1 studies. 
• However, a recent review concluded that the system requires substantial modernization to meet international standards and support the growing number of global clinical trials. 
• In addition, duplicate subjects in clinical trials have become a growing concern in phase II and phase III trials as well. 
• After extensive evaluation, the Verified Clinical Trials platform - widely adopted as the global standard - was selected as the best solution and replacement.

Trial initiated in Japan

• With the support of MRJ, which was commissioned by JACIC to assist with domestic implementation, Verified Clinical Trials has begun initiating sites in Japan, with additional sites expected to join in the coming weeks and months. 
• These sites will benefit from the biometric capabilities of the VCT system, offering a higher level of subject authentication and protocol compliance. 
• This rollout will include sites conducting phase I through phase IV clinical trials.

Statement from the side of MRJ

Given the sophisticated functionality and biometric identification capability of the Verified Clinical Trials system, as well as its proven match for other Asian countries,” a representative of MRJ commented, “I believe it is destined to become the new Japan standard for duplicate subject registration prevention.”

Preventing clinical duplication

Verified Clinical Trials brings to Japan a cross-sponsor, cross-therapeutic area subject registry already in use in up to 40 countries. The platform not only detects but also prevents duplicate subjects and other protocol violations at the time of screening - and maintains protections throughout the entire duration of the trial.

Words from CEO of Verified Clinical Trials

We’re honored to bring Verified Clinical Trials to Japan as part of a shared mission to raise the standard of subject protection and trial integrity,” said Mitchell Efros, president & CEO of Verified Clinical Trials. “No clinical trial or geography is immune to the challenge of duplicate subjects - it’s a global phenomenon. Our system provides an effective, scalable solution.”

From vice president of Verified Clinical Trials

By introducing Verified Clinical Trials in Japan, sponsors gain a real-time tool to proactively manage protocol risk and ensure only qualified participants are enrolled,” added Kerri Weingard, ANP, vice president and COO of Verified Clinical Trials.

From Global regulatory director at Verified Clinical Trials

This launch represents our commitment to regulatory excellence and regional partnership across the APAC region,” said Eve Hsu, global regulatory director at Verified Clinical Trials. “With dedicated team members based throughout APAC, we’re well-positioned to support sites and sponsors locally and help elevate clinical trial quality and compliance across the region.”

About the trial system 

The Verified Clinical Trials system was co-founded by Mitchell Efros, MD, and Kerri Weingard, ANP, both experienced clinical researchers who developed the registry to address long-standing challenges in subject eligibility, data quality, and compliance.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!